June 24, 2010

Dear Us TOO Support Group/Chapter Leaders and Friends,

What an exciting time in the prostate cancer world of late! Both the May and June AUA and the ASCO annual meetings featured much discussion about prostate cancer developments, some highlighted in this July edition of the HotSheet.

As we saw in the June edition of the HotSheet, the FDA approved Dendreon’s sipuleucel-T (Provenge) after a long and complex review process. Now, just as we went to press with this July edition, we see that the FDA has also approved sanofi-aventis’s cabazitaxel (Jevtana). Both developments open new options for men living with the challenges of advanced disease. It has been years we have waited for such developments.

As we wrap-up June and enter the second half of the year our eyes begin to focus on the upcoming months ahead. Last month we shared a flyer on the July 5-11, 2010 Birdies for Charity event which Bill Palos from the Quad Cities Chapter and this office are fully behind. We plan to send another reminder about this great opportunity to raise some money for Us TOO but let us know if we can help you participate.

Please encourage others to attend and please plan to join us in Chicago on August 20-21 for the Us TOO 20th Anniversary celebration event and meet and greet the leaders and active players in Us TOO. Come and learn from a collection of survivors, physicians and researchers knowledgeable about the good news and the challenges we face. Chicago is a wonderful place to be in August, we have sent you materials and you can call or go to the Us TOO website to find more information.

In closing please note that Us TOO is seeking volunteers to serve as leaders and members of the Board. I am so pleased to see the reflections of Greg and Carl about their service on the Board which should give some insight into what it is like to work as a volunteer leading our organization.

Sincerely,

Thomas N. Kirk, President and CEO